	US 11,938,110 B2
	Use of verapamil for the treatment of SARS-Cov-2 induced COVID-19
Manoj P. Jadhav, Hillsborough, NJ (US); and Ramakrishna Devarakonda, Richmond, TX (US)
Filed by Manoj P. Jadhav, Hillsborough, NJ (US)
Filed on Apr. 20, 2023, as Appl. No. 18/304,306.
Application 18/304,306 is a continuation of application No. 17/234,112, filed on Apr. 19, 2021.
Claims priority of provisional application 63/016,595, filed on Apr. 28, 2020.
Prior Publication US 2023/0255924 A1, Aug. 17, 2023
Int. Cl. A61K 31/277 (2006.01); A61K 9/00 (2006.01); A61K 47/02 (2006.01); A61P 31/14 (2006.01)

CPC A61K 31/277 (2013.01) [A61K 9/0078 (2013.01); A61K 47/02 (2013.01); A61P 31/14 (2018.01)]

2 Claims

1. A method for treating SARS-CoV-2 induced COVID-19 in a person who has tested positive for SARS-CoV-2 induced COVID-19, the method comprising administering to the person a pharmaceutically acceptable composition containing a calcium channel blocker component via nasal administration, the calcium channel blocker component comprising an amount of verapamil that is effective to treat the SARS-CoV-2 induced COVID-19, wherein a) the concentration of verapamil in the composition is 15-25 mg/mL, b) the composition is maintained at a pH between 4.09 and 6.09 prior to administration, and c) the composition is administered through a nasal spray device.